Target intelligence / Profile preview

Major histocompatibility complex class II, DR beta 9 chain (HLA-DRB9)

Target
HLA-DRB9
Molecular classification
Receptor, Cell surface protein, Immune molecule, Heterodimer (with DR alpha chain), Antigen presentation complex
01

Overview

Major histocompatibility complex class II, DR beta chain (commonly referred to as the HLA-DRB chain) is an integral membrane protein forming the beta subunit of the HLA-DR antigen-presenting heterodimer. Together with the DR alpha chain, it constitutes the binding groove for peptide antigens derived from extracellular proteins. This complex is a cornerstone of the adaptive immune response, as it presents processed antigens to CD4+ helper T cells, orchestrating immunity and tolerance[1][2][3]. The gene encoding this chain is highly polymorphic, with multiple alleles conferring susceptibility to autoimmune disease, resistance to infections, and influencing transplant compatibility. While "DR beta 9" is not recognized as a canonical, functional human DR beta locus, the general biological role of the DR beta chain is critical in immune system regulation and disease pathogenesis. *If more precise information about “DR beta 9” is required (e.g., its sequence, expression, or disease linkage), authoritative immunogenetic resources should be consulted as this designation appears non-standard or improperly referenced.*

Other names
Major histocompatibility complex class II, DR beta chainHuman leukocyte antigen DR beta chainHLA-DR beta chainHLA-DRB chain
02

Mechanism of action

Blockade of antigen presentation; Inhibition of T cell activation; Reduction of immune response or autoimmunity; Modulation of MHC class II expression at the transcriptional level

03

Biological functions

Immune responseAntigen presentation to CD4+ T cellsAdaptive immunityModulation of immune toleranceActivation of helper T cells
04

Disease associations

Autoimmune diseaseInflammationInfectionCancer (immunosurveillance, immune evasion)Immunodeficiency (mutations, expression loss)
05

Safety considerations

Immunosuppression (increased risk of infection, malignancy)Graft rejection (transplant compatibility issues)Autoimmunity (HLA-DR alleles conferring disease susceptibility)Cytokine release syndrome (rare, mainly in antibody therapy)
06

Interacting drugs

Monoclonal antibodies used for immunosuppression

5 more in the full profile.

07

Biomarkers

HLA-DR beta chain expression (flow cytometry, immunohistochemistry)Soluble HLA-DR molecules (serum/plasma, rarely used in clinical practice)Genetic typing for HLA-DR alleles (association with autoimmune disease risk, graft rejection, etc.)

Beyond the preview

Go deeper on Major histocompatibility complex class II, DR beta 9 chain (HLA-DRB9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Major histocompatibility complex class II, DR beta 9 chain (HLA-DRB9).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call